
Josef Leibold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8299442/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 2020, 583, 127-132.	27.8	483
2	Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine, 2019, 25, 82-88.	30.7	329
3	NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science, 2018, 362, 1416-1422.	12.6	267
4	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nature Medicine, 2014, 20, 1138-1146.	30.7	242
5	Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell, 2020, 181, 424-441.e21.	28.9	216
6	Quantitative self-assembly prediction yields targeted nanomedicines. Nature Materials, 2018, 17, 361-368.	27.5	141
7	Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. Hepatology, 2019, 69, 1768-1786.	7.3	111
8	The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. Cell, 2019, 178, 807-819.e21.	28.9	96
9	Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants. Nature Biotechnology, 2022, 40, 862-873.	17.5	44
10	Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis. Cancer Discovery, 2020, 10, 1038-1057.	9.4	37
11	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	33
12	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	9.4	7
13	Induction of Thelper1-driven Antiviral T-cell Lines for Adoptive Immunotherapy Is Determined by Differential Expression of IFN-Î ³ and T-cell Activation Markers. Journal of Immunotherapy, 2012, 35, 661-669.	2.4	6
14	Differential expression of T _{HELPER} 1 cytokines upon antigen stimulation predicts <i>ex vivo</i> proliferative potential and cytokine production of virusâ€specific T cells following reâ€stimulation. Transplant Infectious Disease, 2014, 16, 713-723.	1.7	0
15	Calibrated CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency. Blood, 2018, 132, 1412-1412.	1.4	0